Peer-Reviewed Journal Details
Mandatory Fields
Connor, TJ,Kelly, JP
2002
November
European Journal Of Pharmacology
Fenfluramine-induced immunosuppression: an in vivo analysis
Published
()
Optional Fields
fenfluramine lipopolysaccharide interleukin-1 beta TNF-alpha (tumor necrosis factor-alpha) interleukin-10 glucocorticoid catecholamine TUMOR-NECROSIS-FACTOR INFLAMMATORY-BOWEL-DISEASE TNF-ALPHA METHYLENEDIOXYMETHAMPHETAMINE MDMA INTERLEUKIN-10 BETA RAT CORTICOSTERONE EXPRESSION SECRETION
455
175
185
We examined the immunomodulatory potential of acute fenfluramine administration, by measuring production of the pro-inflammatory cytokines interleukin (IL)-1beta and tumor necrosis factor (TNF)-alpha in response to an in vivo challenge with bacterial lipopolysaccharide in rats. Fenfluramine (2.5-10 mg/kg) suppressed tumor necrosis factor-alphaproduction, but only fenfluramine (5 and 10 mg/kg) suppressed interleukin-1 p production. Fenfluramine (10 mg/kg)-induced suppression of interleukin- I and tumor necrosis factor-a production persisted for 6 and 24 h, respectively. Using in vitro analyses, we demonstrated that the immunosuppressive effect of fenfluramine was not due to a direct effect on immune cells. As fenfluramine activates the hypothalamic pituitary adrenal axis, we examined the ability of the glucocorticoid receptor antagonist mifepristone to block fenfluramine-induced immunosuppression. However, mifepristone (10 mg/kg) failed to attenuate the suppressive effect of fenfluramine on interleukin-1beta and tumor necrosis factor-alpha production, indicating that glucocorticoids do not mediate fenfluramine-induced immunosuppression. We also assessed the effect of fenfluramine on production of the anti-inflammatory cytokine interieukin-10, as interleukin-10 can suppresses pro-inflammatory cytokine production. Fenfluramine (10 mg/kg) increased interleukin-10 production following an in vivo lipopolysaccharide challenge. However, the ability of fenfluramine to suppress tumor necrosis factor-alphaproduction cannot be accounted for by increased interleukin-10 production, as pretreatment with the beta-adrenoceptor antagonist nadolol completely blocked the increase in interleukin-10 without altering the suppression of tumor necrosis factor-alpha induced by fenfluramine. Taken together, these data demonstrate that fenfluramine promotes an immunosuppressive cytokine phenotype in vivo. The suppression of proinflammatory cytokines is not due to a direct effect the drug on immune cells, and also occurs independently of glucocorticoid receptor activation. In addition, whilst fenfluramine increases production of the anti-inflammatory cytokine interleukin-10, this cannot account for the suppression of the pro-inflammatory cytokine tumor necrosis factor-a induced by fenfluramine. (C) 2002 Elsevier Science B.V. All rights reserved.
PII S0014-2999(02)02588-8
Grant Details
Publication Themes